Literature DB >> 618606

Prolonged atrial conduction. A major predisposing factor for the development of atrial flutter.

C V Leier, J A Meacham, S F Schaal.   

Abstract

Electrophysiological studies were performed during sinus rhythm on 21 patients who had demonstrated the spontaneous occurrence of sustained atrial flutter. The purpose was to determine if atrial conduction disease is a prediposing factor for the development of atrial flutter. Patients with atrial enlargement were excluded from the series. The control group consisted of 11 age-matched patients with normal electrocardiograms and electrophysiology studies. The flutter group showed prolongation of the mean right intra-atrial conduction time at 50 msec (control of 37 msec, P less than 0.05), the mean interatrial conduction time at 92 msec (control of 44 msec, P less than 0.001) and the mean P wave duration at 132 msec (control of 112 msec, P less than 0.01). The flutter group also demonstrated a higher incidence of sinus node dysfunction and ventricular conduction disease compared to the control group. These data indicate that patients who develop atrial flutter have atrial conduction disease. Atrial conduction disease appears to be 1) a major prediposing factor for the development of atrial flutter and 2) a part of the fibro-degenerative conduction disease spectrum.

Entities:  

Mesh:

Year:  1978        PMID: 618606     DOI: 10.1161/01.cir.57.2.213

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

1.  P wave dispersion is prolonged in patients with Wilson's disease.

Authors:  Nurcan Arat; Sabite Kacar; Zehra Golbasi; Meral Akdogan; Yeliz Sokmen; Sedef Kuran; Ramazan Idilman
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

2.  P wave duration and dispersion in multiple sclerosis.

Authors:  Abdulkadir Kocer; Osman Karakaya; Ramazan Kargin; Irfan Barutcu; Ali Metin Esen
Journal:  Clin Auton Res       Date:  2005-12       Impact factor: 4.435

3.  Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy.

Authors:  Carlos Oberti; Lejin Wang; Lin Li; Jiamei Dong; Shaoqi Rao; Wei Du; Qing Wang
Journal:  Circulation       Date:  2004-12-13       Impact factor: 29.690

4.  Increased p-wave duration and p-wave dispersion in patients with aortic stenosis.

Authors:  Hasan Turhan; Ertan Yetkin; Ramazan Atak; Tayfun Altinok; Kubilay Senen; Mehmet Ileri; Hatice Sasmaz; Sengul Cehreli; Emine Kutuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

5.  Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation.

Authors:  Dawood Darbar; Amanda Hardy; Jonathan L Haines; Dan M Roden
Journal:  J Am Coll Cardiol       Date:  2008-03-18       Impact factor: 24.094

6.  Effect of intravenous flecainide on atrial vulnerability in man.

Authors:  T Pop; N Treese; J C Kang; T Meinertz; W Kasper
Journal:  Klin Wochenschr       Date:  1983-06-15

7.  Interatrial block: a novel risk factor for embolic stroke?

Authors:  Vignendra Ariyarajah; Puneet Puri; Sirin Apiyasawat; David H Spodick
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-01       Impact factor: 1.468

8.  Electrophysiologic characteristics of a dilated atrium in patients with paroxysmal atrial fibrillation and atrial flutter.

Authors:  Y J Chen; S A Chen; C T Tai; W C Yu; A N Feng; Y A Ding; M S Chang
Journal:  J Interv Card Electrophysiol       Date:  1998-06       Impact factor: 1.900

9.  Effect of intravenous flecainide on atrial vulnerability in man.

Authors:  T Pop; N Treese
Journal:  Drugs       Date:  1985       Impact factor: 9.546

10.  Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias.

Authors:  J M Starobin; Y I Zilberter; E M Rusnak; C F Starmer
Journal:  Biophys J       Date:  1996-02       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.